Mark Timney has been appointed CEO of The Medicines Company (NASDAQ: MDCO), effective immediately. Timney is also joining the Parsippany, NJ, company’s board of directors. Timney succeeds Clive Meanwell, who is now serving as chief innovation officer. Timney was CEO of Purdue Pharmaceuticals from 2014 to 2017. Before that, he spent six years at Merck (NYSE: MRK) in a number of senior roles. In the past year, The Medicines Company has sold its infectious disease assets and turned its focus to inclisiran, a cholesterol-lowering drug in Phase 3 clinical testing.